JAK inhibitors: a new choice for diabetes mellitus?
Abstract Altered tyrosine kinase signaling is associated with a variety of diseases. Tyrosine kinases can be classified into two groups: receptor type and nonreceptor type. Nonreceptor-type tyrosine kinases are subdivided into Janus kinases (JAKs), focal adhesion kinases (FAKs) and tec protein tyros...
Saved in:
Main Authors: | Mengjun Zhou, Qi Shen, Bo Li |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | Diabetology & Metabolic Syndrome |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13098-025-01582-2 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Baricitinib represses the myocardial fibrosis via blocking JAK/STAT and TGF-β1 pathways in vivo and in vitro
by: Renlei Feng, et al.
Published: (2025-01-01) -
Monocyte STAT1 phosphorylation and treatment response of JAK inhibitors in chronic nonbacterial osteomyelitis
by: Motoshi Sonoda, et al.
Published: (2025-01-01) -
Bullous pemphigoid treated with baricitinib as steroid-sparing therapy for a patient with uncontrolled diabetes
by: Ji Won Heo, MD, et al.
Published: (2025-03-01) -
Osimertinib exacerbates immune checkpoint inhibitor-related severe adverse events by activating the IL-6/JAK/STAT3 pathway in macrophages
by: Yuan Li, et al.
Published: (2024-12-01) -
Impact in Clinical Practice of the European Medicines Agency Health Alert About the Restriction of the Use of JAK Inhibitors
by: Elisabet Castañeda-Estévez, et al.
Published: (2024-12-01)